Pfizer Stops Development of Obesity & Diabetes Pill Over Safety Issues 🚫
Pfizer has halted progress on its experimental obesity and diabetes medication, lotiglipron, citing safety concerns. The company will now focus on its other oral obesity drug, danuglipron.
About this video
Pfizer has ceased development of its experimental obesity and diabetes pill, lotiglipron, and will focus on its other oral obesity drug, danuglipron, which has shown promising results in phase two clinical trials. Plans for phase three trials are expected by the end of 2023.
Video Information
Views
7
Total views since publication
Duration
0:48
Video length
Published
Jun 26, 2023
Release date
About the Channel
Related Trending Topics
LIVE TRENDSThis video may be related to current global trending topics. Click any trend to explore more videos about what's hot right now!
THIS VIDEO IS TRENDING!
This video is currently trending in Colombia under the topic 'estadísticas de selección de fútbol de colombia contra selección de fútbol de nueva zelanda'.
Share This Video
SOCIAL SHAREShare this video with your friends and followers across all major social platforms including X (Twitter), Facebook, Youtube, Pinterest, VKontakte, and Odnoklassniki. Help spread the word about great content!